Pharmacytimes: Resources: Neurology Neurology en-us Sun, 16 Jun 2019 03:39:32 UTC Sun, 16 Jun 2019 03:39:32 UTC Trending News Today: FDA to Review Ozanimod for Relapsing Multiple Sclerosis Top news of the day from across the health care landscape. Co-pay Accumulator Programs: The Debate Continues Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers (PBMs), and manufacturers to reduce drug spend. Study Moves Closer to Identifying Cause of Multiple Sclerosis Investigators aim to develop cellular models to mimic the biological processes responsible for the onset of multiple sclerosis. Study: Obesity May Exacerbate Inflammation, Disability in Multiple Sclerosis Obesity may increase severity of disability in patients with relapsing-remitting multiple sclerosis. What Are the Challenges Involved in Establishing a Successful Specialty Pharmacy? Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, provides insight into some of the challenges associated with establishing or expanding specialty pharmacy services and how to overcome them. Statin Benefit in Multiple Sclerosis Not Due to Cholesterol-Lowering Effects Statins can benefit patients with secondary progressive multiple sclerosis for reasons unrelated to their cholesterol-lowering effects. Free Drug Starter Programs Are Not All Alike Although free drug starter programs are commonplace in the specialty pharmacy space, they vary widely in the marketplace. Higher Ocrelizumab Exposure Further Reduces Disability Progression in MS New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression. Analysis: Oral Ozanimod Reduces Brain Volume Loss in Relapsing MS Compared with interferon beta-1a, ozanimod reduced less cortical grey matter volume in patients with relapsing forms of multiple sclerosis. New Data Show Potential of Investigational Drug for Genetic Form of ALS An investigational therapy for amyotrophic lateral sclerosis has shown promise in slowing the progression of the disease in patients with a genetic form of the disease. Multiple Sclerosis: The Central Nervous System Destroyer There is no cure for multiple sclerosis, but there are more than a dozen treatment options that aid in reducing the severity of the disease. Study Shows Beta Interferon Treatment Improves Long-Term Survival in MS Patients taking beta interferons for at least 6 months had a reduced mortality risk compared with patients who did not take the drug. Drug for Multiple Sclerosis Shows Promise for Epilepsy Treatment The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients Synthetic Molecule May Promote Remyelination, Shows Promise for Multiple Sclerosis Sobetirome was shown to stimulate myelination in mice without the severe adverse effects commonly associated with thyroid hormone therapy for multiple sclerosis. FDA Accepts Riluzole Oral Film New Drug Application for ALS Riluzole oral film is a novel formulation of riluzole, which is an adjuvant therapy for amyotrophic lateral sclerosis. Addressing Challenges of Specialty Pharmacy Expansion in Health Systems Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses the challenges associated with establishing or expanding specialty pharmacy services within an institution. Senate Hearing Addresses Role of Pharmacy Benefit Managers in Drug Pricing On Tuesday, a US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients. Study Shows Patients Commonly Misdiagnosed with Multiple Sclerosis Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers. Targeting Brain Stem Cell Aging in Progressive MS May Enhance Remyelination Brain stem cells of patients with primary progressive multiple sclerosis appear to age faster. Gene Expression Mapping of ALS Could Reveal New Treatment Targets The matching of optimized technologies and novel approaches has provided investigators with a framework to assess and understand neurologic conditions. VSEO N/A